Terms: = Testicular cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
59 results:
1. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
2. Effects of cadmium exposure during pregnancy on genome-wide DNA methylation and the CREB/CREM pathway in the testes of male offspring rats.
Du X; Zhu J; Xu X; Lu Z; Li X; Li Y; Luo L; Zhang W; Liu J
Chemosphere; 2024 Feb; 349():140906. PubMed ID: 38092170
[TBL] [Abstract] [Full Text] [Related]
3. Cadmium and lead implication in testis cancer; is there a connection?
Anđelković M; Djordjevic AB; Vukelić D; Đukić-Ćosić D; Aćimović M; Bojanić N; Bartolović D; Bulat P; Antonijević B; Bulat Z
Chemosphere; 2023 Jul; 330():138698. PubMed ID: 37062390
[TBL] [Abstract] [Full Text] [Related]
4. Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis.
Cosci I; Grande G; Di Nisio A; Rocca MS; Del Fiore P; Benna C; Mocellin S; Ferlin A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614041
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies.
Giampietri C; Scatozza F; Crecca E; Vigiano Benedetti V; Natali PG; Facchiano A
J Transl Med; 2022 Oct; 20(1):467. PubMed ID: 36224560
[TBL] [Abstract] [Full Text] [Related]
6. Benchmark dose approach in investigating the relationship between blood metal levels and reproductive hormones: Data set from human study.
Baralić K; Javorac D; Marić Đ; Đukić-Ćosić D; Bulat Z; Antonijević Miljaković E; Anđelković M; Antonijević B; Aschner M; Buha Djordjevic A
Environ Int; 2022 Jul; 165():107313. PubMed ID: 35635964
[TBL] [Abstract] [Full Text] [Related]
7. Sub-chronic cadmium and lead compound exposure induces reproductive toxicity and development of testicular germ cell neoplasia in situ in murine model: Attenuative effects of resveratrol.
Mitra S; Patra T; Saha D; Ghosh P; Mustafi SM; Varghese AC; Murmu N
J Biochem Mol Toxicol; 2022 Jul; 36(7):e23058. PubMed ID: 35362238
[TBL] [Abstract] [Full Text] [Related]
8. Protective effects of tadalafil against cisplatin-induced spermatogenic dysfunction.
Kaku Y; Chiba K; Sato K; Onishi A; Ishida T; Okada K; Fujisawa M
Biochem Biophys Res Commun; 2022 May; 603():123-129. PubMed ID: 35287053
[TBL] [Abstract] [Full Text] [Related]
9. Pan-cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract] [Full Text] [Related]
10. Cognitive changes and brain connectomes, endocrine status, and risk genotypes in testicular cancer patients-A prospective controlled study.
Buskbjerg CR; Amidi A; Agerbaek M; Gravholt CH; Hosseini SH; Zachariae R
Cancer Med; 2021 Sep; 10(18):6249-6260. PubMed ID: 34390226
[TBL] [Abstract] [Full Text] [Related]
11. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn RE; Hamid O; de Vries EG; Ott PA; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Cho DC; Plummer R; Stroh M; Lu L; Thistlethwaite F
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301808
[TBL] [Abstract] [Full Text] [Related]
12. Accelerated and Improved Vascular Maturity after Transplantation of testicular Tissue in Hydrogels Supplemented with VEGF- and PDGF-Loaded Nanoparticles.
Del Vento F; Poels J; Vermeulen M; Ucakar B; Giudice MG; Kanbar M; des Rieux A; Wyns C
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071329
[TBL] [Abstract] [Full Text] [Related]
13. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Ashkar R; Feldman DR; Adra N; Zaid MA; Funt SA; Althouse SK; Perkins SM; Snow CI; Lazzara KM; Sego LM; Quinn DI; Hanna NH; Einhorn LH; Albany C
Invest New Drugs; 2021 Dec; 39(6):1656-1663. PubMed ID: 34031784
[TBL] [Abstract] [Full Text] [Related]
14. Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.
Hinojosa-Amaya JM; Lam-Chung CE; Cuevas-Ramos D
Front Endocrinol (Lausanne); 2021; 12():657382. PubMed ID: 33986726
[TBL] [Abstract] [Full Text] [Related]
15. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
16. Is low-level metal exposure related to testicular cancer?
Tariba Lovaković B; Živković Semren T; Safner T; Gamulin M; Soče M; Pizent A
J Environ Sci Health C Toxicol Carcinog; 2021; 39(1):87-107. PubMed ID: 33576713
[TBL] [Abstract] [Full Text] [Related]
17. Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
Sardana R; Mishra SK; Williamson SR; Mohanty A; Mohanty SK
Semin Oncol; 2020 Dec; 47(6):367-379. PubMed ID: 33160642
[TBL] [Abstract] [Full Text] [Related]
18. Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.
Dubey D; Wilson MR; Clarkson B; Giannini C; Gandhi M; Cheville J; Lennon VA; Eggers S; Devine MF; Mandel-Brehm C; Kryzer T; Hinson SR; Khazaie K; Hales C; Kattah J; Pavelko KD; Andrews P; Eaton JE; Jitprapaikulsan J; Mills JR; Flanagan EP; Zekeridou A; Leibovich B; Fryer J; Torre M; Kaufman C; Thoreson JB; Sagen J; Linnoila JJ; DeRisi JL; Howe CL; McKeon A; Pittock SJ
JAMA Neurol; 2020 Nov; 77(11):1420-1429. PubMed ID: 32744608
[TBL] [Abstract] [Full Text] [Related]
19. The immunotherapy revolution in genitourinary malignancies.
U Gandhy S; Madan RA; Aragon-Ching JB
Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
[TBL] [Abstract] [Full Text] [Related]
20. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
Sharman JP; Wheler JJ; Einhorn L; Dowlati A; Shapiro GI; Hilton J; Burke JM; Siddiqi T; Whiting N; Jalal SI
Invest New Drugs; 2019 Aug; 37(4):738-747. PubMed ID: 30993587
[TBL] [Abstract] [Full Text] [Related]
[Next]
